Showing results (591-600 of 776) with videos related to
Sort By:
Pageof 78
Health and Quality of Life Outcomes|November 14, 2003
Validity and reliability of patient reported outcomes used in psoriasis: results from two randomized clinical trialsRichard Shikiar, Brian W Bresnahan, Stephen P Stone, et al.Journal of Drugs in Dermatology : JDD|April 10, 2020
Treatment of Plaque Psoriasis With an Excimer Laser Utilizing an Optimal Therapeutic UVB Dose ProtocolQuinn Thibodeaux, Kristen Beck, Benjamin N Lockshin, et al.Interface Focus|December 9, 2024
Robust data-driven segmentation of pulsatile cerebral vessels using functional magnetic resonance imagingAdam M Wright, Tianyin Xu, Jacob Ingram, et al.Biorxiv : the Preprint Server for Biology|August 2, 2024
Robust data-driven segmentation of pulsatile cerebral vessels using functional magnetic resonance imagingAdam M Wright, Tianyin Xu, Jacob Ingram, et al.Dermatology and Therapy|April 4, 2024
Improvements in Psoriasis-Related Work Productivity with Tildrakizumab: Results from a Phase 4 Real-World Study in Patients with Moderate-to-Severe Plaque PsoriasisTina Bhutani, John Koo, Jayme Heim, et al.Skin (Milwood, N.Y.)|September 26, 2024
Treating Chronic Pruritus: Are We at the Threshold of a Breakthrough?Payton Smith, Allison Kranyak, Chandler E Johnson, et al.The Journal of Dermatological Treatment|July 22, 2024
Long-term quality of life outcomes from a phase 4 study of tildrakizumab in patients with moderate-to-severe plaque psoriasis in a real-world settingNeal Bhatia, Jayme Heim, J Gabriel Vasquez, et al.Journal of the American Academy of Dermatology|October 3, 2006
Clinical response to adalimumab treatment in patients with moderate to severe psoriasis: double-blind, randomized controlled trial and open-label extension studyKenneth B Gordon, Richard G Langley, Craig Leonardi, et al.Journal of the American Academy of Dermatology|August 12, 2015
Ustekinumab in adolescent patients age 12 to 17 years with moderate-to-severe plaque psoriasis: results of the randomized phase 3 CADMUS studyIan Landells, Colleen Marano, Ming-Chun Hsu, et al.The Journal of Allergy and Clinical Immunology|March 15, 2015
Anti-IL-23A mAb BI 655066 for treatment of moderate-to-severe psoriasis: Safety, efficacy, pharmacokinetics, and biomarker results of a single-rising-dose, randomized, double-blind, placebo-controlled trialJames G Krueger, Laura K Ferris, Alan Menter, et al.Pageof 78